Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Chinese Journal of Burns ; (6): 107-110, 2008.
Artículo en Chino | WPRIM | ID: wpr-347630

RESUMEN

<p><b>OBJECTIVE</b>To evaluate the efficacy and safety of recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) hydrogel in wound healing in patients with deep partial thickness burn.</p><p><b>METHODS</b>The study was a multicenter, randomized, double-blind, placebo-controlled parallel clinical trial. Three hundred and twenty-one patients (302 cases finally fulfilled the protocol) with deep partial thickness burn were divided into A group (n = 200, with treatment of rhGM-CSF hydrogel, 100 microg/10 g/100 cm2/d), C group (n = 102,with treatment of placebo). Side-effect, systemic condition, wound healing time, wound healing rate, and total effective rate at different time points were observed.</p><p><b>RESULTS</b>There were no obvious differences in vital signs, wound secretion, wound edge reaction, blood and urine routine, liver and kidney function between two groups (P > 0.05). No side-effect was observed. The median wound healing time was 17 days in A group, which was obviously shorter than that in C group (20 days, P < 0.01). The mean wound healing rate in A group was 24.5%, 70.5%, 95.3%, 99.6% respectively on 8th, 14th, 20th, 28th day after treatment, which were obviously higher than that in C group (15.1%, 51.4%, 84.6%, 97.1%, respectively, P < 0.01). The total effective rates in A group on 8th, 14th, 20th day after treatment were also higher than that in C group (P < 0.01).</p><p><b>CONCLUSION</b>rhGM-CSF hydrogel can significantly accelerate wound healing in patients with deep partial thickness burn with certain safety.</p>


Asunto(s)
Femenino , Humanos , Masculino , Quemaduras , Quimioterapia , Método Doble Ciego , Factor Estimulante de Colonias de Granulocitos y Macrófagos , Usos Terapéuticos , Hidrogeles , Usos Terapéuticos , Placebos , Proteínas Recombinantes , Cicatrización de Heridas
2.
Acta Pharmaceutica Sinica ; (12): 257-262, 2007.
Artículo en Chino | WPRIM | ID: wpr-281911

RESUMEN

Nordy is a synthesized chrial compound. To investigate the effects of nordy (25 - 100 micromol x L(-1)) on the function of formylpeptide receptor (FPR) of malignant human glioma cells, human glioblastoma cell line U87 was used to detect its proliferation, migration, calcium mobilization, vascular endothelial growth factor (VEGF) mRNA and protein levels after activation of FPR by its agonist N-formyl-methionyl-leucyl-phenylalanine (fMLF). Cell proliferation, migration ability, VEGF mRNA, VEGF protein and calcium mobilization were evaluated by cell counting, chemotaxis assay, RT-PCR, ELISA and spectrometry. Nordy (50 - 100 micromol x L(-1)) potently inhibited the proliferation, migration and calcium mobilization of U87 cells induced by fMLF (P < 0.05). Moreover, 100 micromol x L(-1) nordy showed a significantly impaired VEGF mRNA expression and protein secretion induced by fMLF (P < 0.05). Nordy could inhibit FPR functioning in glioma cell proliferation, migration and angiogenesis, which might be a possible mechanism of its anti-cancer effects.


Asunto(s)
Humanos , Antineoplásicos , Farmacología , Calcio , Metabolismo , Línea Celular Tumoral , Movimiento Celular , Proliferación Celular , Relación Dosis-Respuesta a Droga , Ensayo de Inmunoadsorción Enzimática , Glioblastoma , Genética , Metabolismo , Patología , Masoprocol , Farmacología , N-Formilmetionina Leucil-Fenilalanina , Farmacología , ARN Mensajero , Genética , Receptores de Formil Péptido , Metabolismo , Fisiología , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Espectrofotometría , Métodos , Factor A de Crecimiento Endotelial Vascular , Genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA